Investing Profile

Markus Goebel

Advisor
CEO at M&G Advisors GmbH
Switzerland
Photo of Markus Goebel, M&G Advisors GmbH

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Novartis Network
71 CONNECTIONS
Novartis Network
71 CONNECTIONS
Roche Network
46 CONNECTIONS
Universität Hamburg Network
14 CONNECTIONS
University of Hamburg Network
13 CONNECTIONS
cb
5
CompanyStageDateRound SizeTotal Raised
Merganser Biotech
Series AFeb 2015$28M
$28M
Co-investors: James N. Topper (Xelas Consulting LLC)
Sorbent Therapeutics
Series DMay 2014$7M
Series CAug 2012$18M
Series BJun 2011$36M
$86M
Co-investors: Scott Minick (ARCH Venture Partners)
Trellis Bioscience
Series BFeb 2007$10M
$10M
Expert Innosuisse2022 - Present
CEO M&G Advisors GmbH2019 - Present
Medical Manager Oncology & Medical Science Farmitalia Carlo Erba-PharmaciaPresent
Several Marketing & Strategy positions incl. an alliance with Amgen F. Hoffmann-La Roche LtdPresent
Director HAYA TherapeuticsPresent
Director hemotune AGPresent
Director OSE ImmunotherapeuticsPresent
Founder & CEO Novartis Venture FundPresent
Director HAYA Therapeutics SA2020 - 2020
Managing Director Novartis Venture Fund2004 - 2019
Head Pharma Corporate M&A Novartis2002 - 2004
Head Nervous System BD&L Pharma Novartis2000 - 2002
Several Marketing & Strategy positions incl. an alliance with Amgen Roche1992 - 1999
Medical Manager Oncology & Medical Science FARMITALIA CARLO ERBA LIMITED1990 - 1992
Henley Management College MBA
Ludwig-Maximilians Universität München MD
Universität Hamburg PhD ADPRibosylation
Henley Business School Master of Business Administration - MBA
Ludwig-Maximilians Universität München Doctor of Medicine - MD
University of Hamburg PhD ADPRibosylation
Sign in with Google →
Sign in with Google →